Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer

BACKGROUND: Immune checkpoint blockade therapy has clearly shown clinical activity in patients with triple-negative breast cancer, but less than half of the patients benefit from the treatments. While a number of ongoing clinical trials are investigating different combinations of checkpoint inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hanwen, Ma, Huilin, Sové, Richard J, Emens, Leisha A, Popel, Aleksander S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883871/
https://www.ncbi.nlm.nih.gov/pubmed/33579739
http://dx.doi.org/10.1136/jitc-2020-002100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883871/
https://www.ncbi.nlm.nih.gov/pubmed/33579739
http://dx.doi.org/10.1136/jitc-2020-002100

Ejemplares similares